Search Results

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
Jarushka Naidoo
Aug 1, 2024, 13:27 | Blog
Rahul Gosain: How will the data from WCLC24 impacts our day to day clinical practice
Rahul Gosain shared a post on LinkedIn: "WCLC24 ~5 weeks away! Let discuss the current…
Jul 30, 2024, 06:39 | Insight
Ph II KUPENG trial of Vebreltinib in Advanced MetExon14 and NSCLC
Jarushka Naidoo shared a post on X about a recent paper by Jin-Ji Yang et…
Jul 22, 2024, 02:59 | Blog
CtDNA Analysis on Osimertinib in FLAURA and AURA3 trials
Jarushka Naidoo shared a post on X about an article by Jhanelle Gray et al. titled…
Jul 21, 2024, 20:02 | Blog
Biagio Ricciuti: Join us in Lausanne for the 2024 International Lung Cancer Summit
Biagio Ricciuti shared a post on X by the International Lung Cancer Summit, adding: "Join…
Jul 7, 2024, 15:44 | Blog
Francesco Cortiula: What evidences for the treatment of patients with stage III NSCLC excluded from trials?
Francesco Cortiula, Medical Oncologist at University Hospital of Udine, made the following post on X:…
Jun 19, 2024, 03:23 | Blog
Alessio Cortellini: A great honor to be invited to the amazing Tbilisi to discuss irAEs-management
Alessio Cortellini, Assistant Professor at Campus Bio-Medico University of Rome, shared a post on LinkedIn: …
Jun 10, 2024, 11:09 | Insight
Phase II BLOSSOM Trial Osimertinib in LMD from EGFR+ NSCLC by Sehhoon Park et al.
Jarushka Naidoo shared a post on X: "Phase II BLOSSOM Trial Osimertinib in LMD (leptomeningeal…
May 25, 2024, 09:19 | Blog
Giannis Mountzios: Don't miss our ASCO24 session on Beyond Chemo-IO in NSCLC
Giannis Mountzios, Medical Oncologist at the Department of Medical Oncology in the Air Force General Hospital…
May 12, 2024, 03:12 | Blog
Misty Dawn Shields: Groundbreaking study challenging the dogma of 'YAP1' neuroendocrine subtype in SCLC
Misty Dawn Shields, Assistant Professor of Clinical Medicine, Division of Hematology/Oncology at IU School of…
Apr 14, 2024, 07:51 | Insight
New Paper Alert! Defining Dermatologic Immune-Related Adverse Events: A Consensus-Driven Approach
Defining Dermatologic Immune-Related Adverse Events: A Consensus-Driven Approach  Published in Journal for ImmunoTherapy of Cancer,…
All: 128 Posts: 81 - 90
Special Coverage